Anzeige
❌
Mehr »
Dienstag, 29.09.2026 - Börsentäglich über 12.000 News
Operation Vivaldi verändert die Kriegsführung: Bodendrohnen-Aktie mit Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
12:46Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline
12:46MSD bets $2.13bn on SciBrunch's KRAS (ON) inhibitor
11:46AstraZeneca to invest $2bn in Summit for ADC combination therapies
11:46Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
MoAbbVie lands FDA approval for next-generation Parkinson's drug, Juvmo
MoNovo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa
MoDaiichi Sankyo, MSD withdraw cancer drug application
MoMirum and Incyte's Atebrioz approved for FOP in US
FrAptar Pharma and Macquarie University partner on drug delivery project
FrFDA commissioner nominee affirms MMR vaccine safety despite Trump's claims
FrRoche and Earendil forge $1.5bn bispecific discovery deal
FrAmberstone and Henlius agree to develop solid-tumour T-cell engagers
FrFDA approves Lilly's Onswik for type 2 diabetes in adults
DoEli Lilly outlays $3.35bn for secretive drug discovery pact with China's InnoCare
DoAustralia starts investigation into OpenAI Medicare breach
DoEnveda nabs $311m to progress nature-derived drug pipeline
DoGenialis and Inventia to enhance pancreatic cancer treatment testing
DoBasecamp Research secures $140m for AI-driven therapies
MiEuropean big pharma unites amid 'ringing alarm bells' of continent's dominance
MiBoehringer and Envisagenics to develop precision cancer therapies in $1bn deal
MiBoomRay and Novartis Pharma sign $900m deal for radioligand therapy
MiBoehringer and Envisagenics to develop precision cancer therapies
22.09.Novo targets blockbuster-heavy 2030 but share slump signals unease
22.09.Made Scientific acquires cell therapy facility in Pennsylvania, US
22.09.EC approves Menarini and NewAmsterdam's obicetrapib therapies